FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2300550500> ?p ?o ?g. }

• W2300550500 endingPage "2643" @default.
• W2300550500 startingPage "2634" @default.
• W2300550500 abstract "Abstract Bacterially synthesized recombinant human granulocyte-macrophage colony- stimulating factor (rhGM-CSF) is an agent with therapeutic potential for neutropenic states, but even at doses below the maximal tolerated dose adverse effects occur during short courses of administration. We have recognized a syndrome of hypoxia and hypotension that follows the first but not subsequent doses of rhGM-CSF. Thirteen of 42 patients receiving rhGM-CSF in phase I studies and 4 of 6 patients in a phase II study developed a reaction that occurred after the first dose of 24 of 78 cycles of rhGM-CSF therapy. The reaction was characterized by flushing (16 of 24), tachycardia (16 of 24), hypotension (14 of 24), musculoskeletal pain (13 of 24), dyspnea (12 of 24), nausea and vomiting (11 of 24), rigors (5 of 24), involuntary leg spasms (3 of 24), and syncope (3 of 24). The reaction did not occur after any of more than 600 second and subsequent consecutive rhGM-CSF doses. Oxygen saturation decreased during first-dose reactions by 8% +/- 4% as compared with 3% +/- 1% on first days without reactions (P less than .001) and 2% +/- 1% on subsequent days (P less than .001). Pulmonary dysfunction was characterized by hypoxemia (59 +/- 9 mm Hg, mean +/- SD) that was fully correctable with supplementary oxygen, decreased single-breath carbon monoxide diffusion capacity, and increased alveolar-arterial oxygen gradients (25 +/- 6 to 60 +/- 4 mm Hg, mean +/- SD), but no significant abnormalities on chest roentgenogram or lung perfusion scan. Factors predisposing to reactions were rhGM-CSF dose greater than or equal to 3 micrograms/kg (P less than .01), intravenous (IV) rather than subcutaneous (SC) administration (P less than .05), occurrence of a reaction after the first dose of a previous cycle of rhGM-CSF therapy (P less than .01), and for patients receiving 15 micrograms/kg/d by SC bolus, the presence of lung cancer (P less than .05). Administration of 15 micrograms/kg/d rhGM-CSF by 24-hour SC infusion rather than SC bolus resulted in a delayed onset of reaction from 30 +/- 8 minutes to 240 +/- 190 minutes (mean +/- SD, P less than .001), and a slower rate of initial transient decrease in neutrophil levels and a more prolonged duration of transient leukopenia. The time of onset of reactions correlated with the rate of rise of rhGM-CSF levels.(ABSTRACT TRUNCATED AT 400 WORDS)." @default.
• W2300550500 created "2016-06-24" @default.
• W2300550500 creator A5031661938 @default.
• W2300550500 creator A5031949010 @default.
• W2300550500 creator A5044014434 @default.
• W2300550500 date "1989-12-01" @default.
• W2300550500 modified "2023-10-16" @default.
• W2300550500 title "Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony- stimulating factor" @default.
• W2300550500 cites W1445198454 @default.
• W2300550500 cites W1544019899 @default.
• W2300550500 cites W1578149674 @default.
• W2300550500 cites W1919752579 @default.
• W2300550500 cites W1965887484 @default.
• W2300550500 cites W1967162647 @default.
• W2300550500 cites W1973034088 @default.
• W2300550500 cites W1974960469 @default.
• W2300550500 cites W1976969755 @default.
• W2300550500 cites W1977157092 @default.
• W2300550500 cites W1978242563 @default.
• W2300550500 cites W1978721894 @default.
• W2300550500 cites W1987307895 @default.
• W2300550500 cites W1991549910 @default.
• W2300550500 cites W2011291552 @default.
• W2300550500 cites W2036068566 @default.
• W2300550500 cites W2040968837 @default.
• W2300550500 cites W2055037877 @default.
• W2300550500 cites W2056225363 @default.
• W2300550500 cites W2066326340 @default.
• W2300550500 cites W2084577908 @default.
• W2300550500 cites W2097779050 @default.
• W2300550500 cites W2103937418 @default.
• W2300550500 cites W2108006679 @default.
• W2300550500 cites W2150781890 @default.
• W2300550500 cites W2215834401 @default.
• W2300550500 cites W2263914605 @default.
• W2300550500 cites W2313477330 @default.
• W2300550500 cites W2317007280 @default.
• W2300550500 cites W2317906013 @default.
• W2300550500 cites W2326695376 @default.
• W2300550500 cites W2337660074 @default.
• W2300550500 cites W2338599277 @default.
• W2300550500 cites W2342420586 @default.
• W2300550500 cites W2407381120 @default.
• W2300550500 cites W2409062727 @default.
• W2300550500 cites W2410421515 @default.
• W2300550500 cites W2413385070 @default.
• W2300550500 cites W2414536272 @default.
• W2300550500 cites W259525224 @default.
• W2300550500 cites W320992867 @default.
• W2300550500 cites W1498404162 @default.
• W2300550500 doi "https://doi.org/10.1182/blood.v74.8.2634.2634" @default.
• W2300550500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2684297" @default.
• W2300550500 hasPublicationYear "1989" @default.
• W2300550500 type Work @default.
• W2300550500 sameAs 2300550500 @default.
• W2300550500 citedByCount "98" @default.
• W2300550500 countsByYear W23005505002015 @default.
• W2300550500 countsByYear W23005505002020 @default.
• W2300550500 crossrefType "journal-article" @default.
• W2300550500 hasAuthorship W2300550500A5031661938 @default.
• W2300550500 hasAuthorship W2300550500A5031949010 @default.
• W2300550500 hasAuthorship W2300550500A5044014434 @default.
• W2300550500 hasBestOaLocation W23005505001 @default.
• W2300550500 hasConcept C126322002 @default.
• W2300550500 hasConcept C146957229 @default.
• W2300550500 hasConcept C178790620 @default.
• W2300550500 hasConcept C185592680 @default.
• W2300550500 hasConcept C197934379 @default.
• W2300550500 hasConcept C2776779939 @default.
• W2300550500 hasConcept C2780580376 @default.
• W2300550500 hasConcept C2780852908 @default.
• W2300550500 hasConcept C42219234 @default.
• W2300550500 hasConcept C540031477 @default.
• W2300550500 hasConcept C71924100 @default.
• W2300550500 hasConcept C7836513 @default.
• W2300550500 hasConcept C90924648 @default.
• W2300550500 hasConceptScore W2300550500C126322002 @default.
• W2300550500 hasConceptScore W2300550500C146957229 @default.
• W2300550500 hasConceptScore W2300550500C178790620 @default.
• W2300550500 hasConceptScore W2300550500C185592680 @default.
• W2300550500 hasConceptScore W2300550500C197934379 @default.
• W2300550500 hasConceptScore W2300550500C2776779939 @default.
• W2300550500 hasConceptScore W2300550500C2780580376 @default.
• W2300550500 hasConceptScore W2300550500C2780852908 @default.
• W2300550500 hasConceptScore W2300550500C42219234 @default.
• W2300550500 hasConceptScore W2300550500C540031477 @default.
• W2300550500 hasConceptScore W2300550500C71924100 @default.
• W2300550500 hasConceptScore W2300550500C7836513 @default.
• W2300550500 hasConceptScore W2300550500C90924648 @default.
• W2300550500 hasIssue "8" @default.
• W2300550500 hasLocation W23005505001 @default.
• W2300550500 hasOpenAccess W2300550500 @default.
• W2300550500 hasPrimaryLocation W23005505001 @default.
• W2300550500 hasRelatedWork W1973491965 @default.
• W2300550500 hasRelatedWork W1980385917 @default.
• W2300550500 hasRelatedWork W2034273687 @default.
• W2300550500 hasRelatedWork W2349236515 @default.
• W2300550500 hasRelatedWork W2350892925 @default.

• next